Table 3. Univariate analysis of potential variables associated with OS and PFS of patients with LS-SCLC.

Variables	Overall survival (N=226)			Progression-free survival (N=226)
	Hazard ratio (95% CI)	P		Hazard ratio (95% CI)	P
Age	0.960 (0.652–1.412)	0.834		0.894 (0.595–1.343)	0.59
Smoking status
Current or ex-smoker	1.407 (1.079–1.835)	0.012		1.145 (0.869–1.509)	0.337
Never Smoker
KPS at diagnosis
≥80	0.757 (0.493–1.162)	0.203		0.845 (0.542–1.319)	0.459
<80
Prophylactic cranial irradiation
Yes	0.900 (0.692–1.170)	0.43		1.086 (0.826–1.428)	0.556
No
Radiotherapy fractionation
Conventional fractionated RT	0.803 (0.603–1.068)	0.132		0.865 (0.646–1.158)	0.33
Hyperfractionated RT
Hemoglobin (Hb)
≥110	0.981 (0.519–1.854)	0.953		0.663 (0.338–1.303)	0.233
<110
Albumin (Alb)
≥35	0.753 (0.420–1.350)	0.341		0.239 (0.118–0.484)	0.003
<35
Lactic dehydrogenase (LDH)
<240	0.939 (0.678–1.301)	0.707		1.061 (0.754–1.493)	0.734
≥240
Alkaline phosphatase (Alp)
≥120	1.389 (0.853–2.260)	0.186		1.283 (0.796–2.069)	0.306
<120
Pre-ALC
<1,780 cells/mm3	1.296 (1.011–1.662)	0.04		1.128 (0.815–1.562)	0.467
≥1,780 cells/mm3
After-ALC
<655 cells/mm3	2.633 (2.025–3.424)	<0.001		2.582 (1.987–3.354)	<0.001
≥655 cells/mm3
Post-ALC
<1,430 cells/mm3	1.812 (1.381–2.378)	0.002		1.573 (1.200–2.063)	0.001
≥1,430 cells/mm3

LS-SCLS, limited-stage small cell lung cancer; ALC, absolute lymphocyte count.